자가면역 관련 제휴 조건과 계약
Global Autoimmune Partnering 2014-2021: Deal trends, players and financials
|발행일 : 2021년 10월 ||페이지 정보 : 영문 700+ Pages
※ 본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.
자가면역(Autoimmune) 관련 제휴 조건과 계약에 대해 조사 분석했으며, 제휴 거래 동향, 평균 거래 조건, 제휴 계약 구조, 제휴 계약 서류, 거래액(금액별), 가장 적극적인 계약 기업 등의 정보를 전해드립니다.
제2장 자가면역 관련 계약 동향
- 자가면역 관련 제휴 추정
- 대형 제약 기업의 자가면역 관련 계약 활동
- 대형 바이오 기업의 자가면역 관련 계약 활동
- 자가면역 관련 제휴에 가장 적극적인 기업
- 자가면역 관련 제휴 : 거래 종류별
- 자가면역 관련 제휴 : 산업 부문별
- 자가면역 관련 제휴 : 개발 단계별
- 자가면역 관련 제휴 : 기술 종류별
- 자가면역 관련 제휴 : 암 적응증별
- 자가면역 관련 평균 거래 조건
제3장 자가면역 관련 주요 거래
제4장 대형 제약 기업의 자가면역 관련 거래
제5장 대형 바이오 기업의 자가면역 관련 거래
제6장 자가면역 관련 제휴 계약 디렉토리
제7장 자가면역 관련 계약 : 적응증별
제8장 제휴 자원 센터
- 온라인 제휴
- 제휴 이벤트
- 계약에 관한 관련 자료
Wildwood Ventures 소개
The Global Autoimmune Partnering 2014-2021: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the autoimmune disease partnering deals and agreements entered into by the worlds leading healthcare companies
Global Autoimmune Partnering 2014 to 2021 provides the full collection of Autoimmune disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.
Trends in Autoimmune partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Autoimmune partnering agreement structure
Autoimmune partnering contract documents
Top Autoimmune deals by value
Most active Autoimmune dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Autoimmune disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Autoimmune deals.
The report includes coverage of the following autoimmune diseases:
- Multiple sclerosis, Restless leg syndrome, Dermatitis, Eczema, Alopecia, Psoriasis, Celiac disease, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Glomerulonephritis, Endometriosis, Immune thrombocytopenic purpura, Neutropenia, Graft versus host disease, Scleroderma, Systemic lupus erythematosus, Addison's disease, Diabetes Type 1, Ankylosing spondylitis, Juvenile arthritis, Psoriatic arthritis, Rheumatoid arthritis, Uveitis, Narcolepsy, Cronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Sarcoidosis, Meniere's disease, and other autoimmune disorders.
- The report presents financial deal terms values for Autoimmune deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
- The initial chapters of this report provide an orientation of Autoimmune dealmaking trends.
- Chapter 1 provides an introduction to the report.
- Chapter 2 provides an overview of the trends in Autoimmune dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
- Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
- Chapter 4 provides a review of the leading Autoimmune deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Autoimmune dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
- Chapter 5 provides comprehensive access to Autoimmune deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
- Chapter 6 provides a comprehensive directory of all Autoimmune partnering deals by specific Autoimmune target announced since 2014. The chapter is organized by specific Autoimmune therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
- In addition, a comprehensive appendix is provided with each report of all Autoimmune partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
- The report also includes numerous tables and figures that illustrate the trends and activities in Autoimmune partnering and dealmaking since 2014.
- In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Autoimmune technologies and products.
Global Autoimmune Partnering 2014 to 2021 provides the reader with the following key benefits:
- In-depth understanding of Autoimmune deal trends since 2014
- Access Autoimmune deal headline, upfront, milestone and royalty data
- Research hundreds of actual contracts between Autoimmune partner companies
- Comprehensive access to over 950 links to actual Autoimmune deals entered into by the world's biopharma companies
- Indepth review of Autoimmune deals entered into by the top 25 most active dealmakers
- Benchmark the key deal terms companies have agreed in previous deals
- Identify key terms under which companies partner Autoimmune opportunities
- Uncover companies actively partnering Autoimmune opportunities
Table of Contents
Chapter 1 - Introduction
Chapter 2 - Trends in Autoimmune dealmaking
- 2.1. Introduction
- 2.2. Autoimmune partnering over the years
- 2.3. Autoimmune partnering by deal type
- 2.4. Autoimmune partnering by industry sector
- 2.5. Autoimmune partnering by stage of development
- 2.6. Autoimmune partnering by technology type
- 2.7. Autoimmune partnering by therapeutic indication
Chapter 3 -Financial deal terms for Autoimmune partnering
- 3.1. Introduction
- 3.2. Disclosed financials terms for Autoimmune partnering
- 3.3. Autoimmune partnering headline values
- 3.4. Autoimmune deal upfront payments
- 3.5. Autoimmune deal milestone payments
- 3.6. Autoimmune royalty rates
Chapter 4 - Leading Autoimmune deals and dealmakers
- 4.1. Introduction
- 4.2. Most active in Autoimmune partnering
- 4.3. List of most active dealmakers in Autoimmune
- 4.4. Top Autoimmune deals by value
Chapter 5 - Autoimmune contract document directory
- 5.1. Introduction
- 5.2. Autoimmune partnering deals where contract document available
Chapter 6 - Autoimmune dealmaking by therapeutic target
- 6.1. Introduction
- 6.2. Deals by Autoimmune therapeutic target
- Appendix 1 - Directory of Autoimmune deals by company A-Z 2014 to 2021
- Appendix 2 - Directory of Autoimmune deals by deal type 2014 to 2021
- Appendix 3 - Directory of Autoimmune deals by stage of development 2014 to 2021
- Appendix 4 - Directory of Autoimmune deals by technology type 2014 to 2021
- Further reading on dealmaking
- Deal type definitions
About Wildwood Ventures
- Current Partnering
- Current Agreements
- Recent report titles from CurrentPartnering
Table of figures
- Figure 1: Autoimmune partnering since 2014
- Figure 2: Autoimmune partnering by deal type since 2014
- Figure 3: Autoimmune partnering by industry sector since 2014
- Figure 4: Autoimmune partnering by stage of development since 2014
- Figure 5: Autoimmune partnering by technology type since 2014
- Figure 6: Autoimmune partnering by indication since 2014
- Figure 7: Autoimmune deals with a headline value
- Figure 8: Autoimmune deals with upfront payment values
- Figure 9: Autoimmune deals with milestone payment
- Figure 10: Autoimmune deals with royalty rates
- Figure 11: Active Autoimmune dealmaking activity- 2014 to 2021
- Figure 12: Top Autoimmune deals by value since 2014